Delivery of the vitamin E compound tocotrienol to cancer cells

Research output: Contribution to journalArticle

  • 2 Citations

Abstract

Tocotrienol, a member of the vitamin E family of compounds, is currently receiving increased attention because of its highly promising anti-cancer effects. However, its potential in cancer therapy is limited by its poor bioavailability and its inability to specifically reach tumors at therapeutic concentrations after intravenous administration. In order to remediate to these problems, various delivery strategies have been proposed, such as the inclusion of tocotrienol in γ-cyclodextrins, prodrugs and emulsions, entrapment in lipid nanoparticles and vesicles.
Among these approaches, we demonstrated that the entrapment of tocotrienol within vesicles bearing transferrin, whose receptors are overexpressed on numerous cancer cells, significantly improved the uptake by cancer cells overexpressing transferrin receptors. Consequently, the intravenous administration of tocotrienol entrapped in transferrin-bearing vesicles led to tumor regression and even complete tumor suppression in some cases in a murine tumor model, as well as improvement of animal survival.
Transferrin-bearing vesicles are therefore highly promising for the delivery of tocotrienol to cancer cells in vitro and in vivo and should be further investigated to optimize the anti-cancer therapeutic effect of tocotrienol.
LanguageEnglish
Pages1385-1389
Number of pages5
JournalTherapeutic Delivery
Volume2
Issue number11
StatePublished - 2011

Fingerprint

Tocotrienols
Vitamin E
Neoplasms
Transferrin Receptors
Transferrin
Intravenous Administration
gamma-Cyclodextrins
Prodrugs
Therapeutic Uses
Emulsions
Nanoparticles
Biological Availability

Keywords

  • tocotrienol
  • cancer therapy
  • delivery system
  • tumor targeting
  • transferring

Cite this

@article{21af8e9a798c4a9c9d6f73f87e20a1c4,
title = "Delivery of the vitamin E compound tocotrienol to cancer cells",
abstract = "Tocotrienol, a member of the vitamin E family of compounds, is currently receiving increased attention because of its highly promising anti-cancer effects. However, its potential in cancer therapy is limited by its poor bioavailability and its inability to specifically reach tumors at therapeutic concentrations after intravenous administration. In order to remediate to these problems, various delivery strategies have been proposed, such as the inclusion of tocotrienol in γ-cyclodextrins, prodrugs and emulsions, entrapment in lipid nanoparticles and vesicles. Among these approaches, we demonstrated that the entrapment of tocotrienol within vesicles bearing transferrin, whose receptors are overexpressed on numerous cancer cells, significantly improved the uptake by cancer cells overexpressing transferrin receptors. Consequently, the intravenous administration of tocotrienol entrapped in transferrin-bearing vesicles led to tumor regression and even complete tumor suppression in some cases in a murine tumor model, as well as improvement of animal survival. Transferrin-bearing vesicles are therefore highly promising for the delivery of tocotrienol to cancer cells in vitro and in vivo and should be further investigated to optimize the anti-cancer therapeutic effect of tocotrienol.",
keywords = "tocotrienol, cancer therapy, delivery system, tumor targeting, transferring",
author = "Christine Duf{\`e}s",
year = "2011",
language = "English",
volume = "2",
pages = "1385--1389",
journal = "Therapeutic Delivery",
issn = "2041-5990",
number = "11",

}

Delivery of the vitamin E compound tocotrienol to cancer cells. / Dufès, Christine.

In: Therapeutic Delivery, Vol. 2, No. 11, 2011, p. 1385-1389.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Delivery of the vitamin E compound tocotrienol to cancer cells

AU - Dufès,Christine

PY - 2011

Y1 - 2011

N2 - Tocotrienol, a member of the vitamin E family of compounds, is currently receiving increased attention because of its highly promising anti-cancer effects. However, its potential in cancer therapy is limited by its poor bioavailability and its inability to specifically reach tumors at therapeutic concentrations after intravenous administration. In order to remediate to these problems, various delivery strategies have been proposed, such as the inclusion of tocotrienol in γ-cyclodextrins, prodrugs and emulsions, entrapment in lipid nanoparticles and vesicles. Among these approaches, we demonstrated that the entrapment of tocotrienol within vesicles bearing transferrin, whose receptors are overexpressed on numerous cancer cells, significantly improved the uptake by cancer cells overexpressing transferrin receptors. Consequently, the intravenous administration of tocotrienol entrapped in transferrin-bearing vesicles led to tumor regression and even complete tumor suppression in some cases in a murine tumor model, as well as improvement of animal survival. Transferrin-bearing vesicles are therefore highly promising for the delivery of tocotrienol to cancer cells in vitro and in vivo and should be further investigated to optimize the anti-cancer therapeutic effect of tocotrienol.

AB - Tocotrienol, a member of the vitamin E family of compounds, is currently receiving increased attention because of its highly promising anti-cancer effects. However, its potential in cancer therapy is limited by its poor bioavailability and its inability to specifically reach tumors at therapeutic concentrations after intravenous administration. In order to remediate to these problems, various delivery strategies have been proposed, such as the inclusion of tocotrienol in γ-cyclodextrins, prodrugs and emulsions, entrapment in lipid nanoparticles and vesicles. Among these approaches, we demonstrated that the entrapment of tocotrienol within vesicles bearing transferrin, whose receptors are overexpressed on numerous cancer cells, significantly improved the uptake by cancer cells overexpressing transferrin receptors. Consequently, the intravenous administration of tocotrienol entrapped in transferrin-bearing vesicles led to tumor regression and even complete tumor suppression in some cases in a murine tumor model, as well as improvement of animal survival. Transferrin-bearing vesicles are therefore highly promising for the delivery of tocotrienol to cancer cells in vitro and in vivo and should be further investigated to optimize the anti-cancer therapeutic effect of tocotrienol.

KW - tocotrienol

KW - cancer therapy

KW - delivery system

KW - tumor targeting

KW - transferring

M3 - Article

VL - 2

SP - 1385

EP - 1389

JO - Therapeutic Delivery

T2 - Therapeutic Delivery

JF - Therapeutic Delivery

SN - 2041-5990

IS - 11

ER -